Targeted therapy is a precision multi omics-enabled therapeutic approach that aims to act on specific molecular vulnerabilities rather than using nonselective treatment, and it is being applied across multiple tumor types and other diseases. In thymic epithelial tumors, it is described as an evolving therapeutic approach, while in esophageal cancer it is framed as a precision treatment modality within recent management advances. The literature also places targeted therapy in the expanding clinical landscape of gastrointestinal cancers, where multi-omics supports combination drug development and the identification of new vulnerable targets. Beyond oncology, it is discussed as a molecular intervention strategy in pulmonary fibrosis and as an emerging therapy for cisplatin-resistant small cell lung cancer, with combination use alongside immunotherapy also evaluated in prostate cancer. A melanoma-related report notes that this newer treatment class can have unique adverse events compared with traditional therapies, underscoring the need for disease-specific safety monitoring. Overall, the cited reviews and clinical studies highlight targeted therapy as a broad, mechanism-driven platform that is increasingly integrated with immunotherapy and biomarker-guided precision medicine.
Thymic epithelial tumors
- Targeted therapy is described as an evolving treatment approach for thymic epithelial tumors in a 2026 Journal of Thoracic Oncology review (PMID:41961041).
- The review places targeted therapy alongside immunotherapy in the management discussion for thymic epithelial tumors (PMID:41961041).
- The article is part of a broader diagnostic and management update from the Thymic Tumor Subcommittee of the IASLC Rare Tumors Committee (PMID:41961041).
Esophageal cancer
- A 2026 Signal Transduction and Targeted Therapy review summarizes recent progress in targeted therapy for esophageal cancer (PMID:41986343).
- The review frames targeted therapy as a precision treatment modality in esophageal cancer management (PMID:41986343).
- The paper is positioned as a pathogenesis-to-precision-therapies overview, linking molecular understanding to treatment selection (PMID:41986343).
Gastrointestinal cancers and multi-omics
- In a 2026 Molecular Cancer review, multi-omics is described as supporting effective drug combinations and the development of therapeutics with new vulnerable targets in gastrointestinal cancers via multi omics (PMID:41992238).
- Targeted therapy is discussed as part of the expanding clinical practice landscape enabled by multi-omics in gastrointestinal tumor biology (PMID:41992238).
- The review emphasizes the translation of omics-derived vulnerabilities into clinical practice for GI malignancies (PMID:41992238).
Lung cancer and pulmonary fibrosis
- Targeted therapy is highlighted as an emerging therapeutic strategy for cisplatin-resistant small cell lung cancer in a 2026 Annals of Medicine paper (PMID:41869709).
- The lung cancer study focuses on novel therapeutic strategies and mechanistic research in the resistant setting (PMID:41869709).
- In pulmonary fibrosis, targeted therapy is presented as a molecular intervention strategy among promising future novel therapies in a 2026 International Journal of Molecular Medicine review (PMID:41789674).
Prostate cancer and melanoma
- A 2026 International Journal of Cancer study evaluated combined immunotherapy and targeted therapy for prostate cancer (PMID:42017392).
- The prostate cancer paper specifically assessed clinical benefit and safety of the combination approach (PMID:42017392).
- In melanoma, targeted therapy is described as a newer treatment with unique adverse events compared with traditional treatments, highlighting distinct toxicity considerations (PMID:42007593).